JP2013525266A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525266A5
JP2013525266A5 JP2012554464A JP2012554464A JP2013525266A5 JP 2013525266 A5 JP2013525266 A5 JP 2013525266A5 JP 2012554464 A JP2012554464 A JP 2012554464A JP 2012554464 A JP2012554464 A JP 2012554464A JP 2013525266 A5 JP2013525266 A5 JP 2013525266A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
seq
synuclein
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012554464A
Other languages
English (en)
Japanese (ja)
Other versions
JP5894939B2 (ja
JP2013525266A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/050826 external-priority patent/WO2011104696A1/en
Publication of JP2013525266A publication Critical patent/JP2013525266A/ja
Publication of JP2013525266A5 publication Critical patent/JP2013525266A5/ja
Application granted granted Critical
Publication of JP5894939B2 publication Critical patent/JP5894939B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012554464A 2010-02-26 2011-02-25 プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 Active JP5894939B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30863810P 2010-02-26 2010-02-26
US61/308,638 2010-02-26
US40626010P 2010-10-25 2010-10-25
US61/406,260 2010-10-25
PCT/IB2011/050826 WO2011104696A1 (en) 2010-02-26 2011-02-25 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

Publications (3)

Publication Number Publication Date
JP2013525266A JP2013525266A (ja) 2013-06-20
JP2013525266A5 true JP2013525266A5 (https=) 2014-05-15
JP5894939B2 JP5894939B2 (ja) 2016-03-30

Family

ID=44227520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012554464A Active JP5894939B2 (ja) 2010-02-26 2011-02-25 プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用

Country Status (20)

Country Link
US (4) US8632776B2 (https=)
EP (1) EP2539366B1 (https=)
JP (1) JP5894939B2 (https=)
CN (3) CN110655573B (https=)
AU (1) AU2011219414B2 (https=)
CA (1) CA2789963C (https=)
CY (1) CY1120014T1 (https=)
DK (1) DK2539366T3 (https=)
ES (1) ES2661925T3 (https=)
HR (1) HRP20180230T8 (https=)
HU (1) HUE038313T2 (https=)
LT (1) LT2539366T (https=)
NO (1) NO2539366T3 (https=)
PL (1) PL2539366T3 (https=)
PT (1) PT2539366T (https=)
RS (1) RS57029B1 (https=)
RU (1) RU2555526C2 (https=)
SI (1) SI2539366T1 (https=)
SM (1) SMT201800044T1 (https=)
WO (1) WO2011104696A1 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
SG10201700735PA (en) * 2012-01-20 2017-02-27 Genzyme Corp Anti-cxcr3 antibodies
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
CA2924268C (en) 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
EP3166970B1 (en) * 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
WO2016040905A1 (en) * 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded alpha synuclein protein
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
US10494425B2 (en) 2015-02-24 2019-12-03 Rpeptide, Llc Anti-amyloid-beta antibodies
EP3091087A1 (en) 2015-05-08 2016-11-09 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
CN109475616B (zh) * 2016-06-02 2022-10-18 麦迪穆有限责任公司 针对α-突触核蛋白的抗体及其用途
RU2019102746A (ru) 2016-07-14 2020-08-14 Биоарктик Аб Белок для транспорта в мозг
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
AR110074A1 (es) 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
CA3049110A1 (en) * 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
CN110506057B (zh) * 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
EP3612566A4 (en) * 2017-04-21 2021-03-03 Implicit Bioscience Limited CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
US11220538B2 (en) 2017-05-01 2022-01-11 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
TW201901153A (zh) 2017-05-16 2019-01-01 美商安培恩股份有限公司 折疊錯誤之tau蛋白的檢測及檢測折疊錯誤之tau蛋白的套組
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
JP7204235B2 (ja) 2017-08-02 2023-01-16 ストレスマーク・バイオサイエンシーズ・インコーポレイテッド 活性型α-シヌクレインに結合する抗体
EP3672635A4 (en) * 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF
RU2657763C1 (ru) * 2017-09-12 2018-06-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики болезни паркинсона
EP3725802A4 (en) * 2017-11-17 2021-08-11 ABL Bio Inc. Antibodies to alpha-synuclein and uses thereof
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
ES2955992T3 (es) 2017-12-19 2023-12-11 Chase Therapeutics Corp Método para evaluar una sinucleinopatía
WO2019121952A1 (en) * 2017-12-21 2019-06-27 H. Lundbeck A/S Assay, method and treatment of alpha-synucleinopathies
CN109957546A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
CN109957547A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
US12583894B2 (en) 2018-04-04 2026-03-24 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of Lewy body disorders
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
MX2021000778A (es) 2018-07-24 2021-03-31 Eisai R&D Man Co Ltd Metodos de tratamiento y prevencion de la enfermedad de alzheimer.
WO2020079113A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
KR20210104094A (ko) * 2018-12-12 2021-08-24 우시 바이올로직스 아일랜드 리미티드 항-tim-3 항체 및 이의 용도
RU2703430C1 (ru) * 2018-12-13 2019-10-16 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
EP3946266A4 (en) * 2019-03-28 2023-07-12 The Chinese University Of Hong Kong SUMO PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CA3136679A1 (en) * 2019-04-30 2020-11-05 Chase Therapeutics Corporation Alpha-synuclein assays
US20220291240A1 (en) * 2019-08-27 2022-09-15 The Johns Hopkins University Biomarkers for neurodegenerative disorders
CA3163308A1 (en) 2019-12-31 2021-07-08 Thomas N. Chase Kinases as biomarkers for neurodegenerative conditions
CN111171152B (zh) * 2020-01-15 2023-04-18 吉林医药学院 Pcsk9抗体及其制备方法和应用
NL2025332B1 (en) 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
RS66984B1 (sr) * 2020-06-26 2025-07-31 Bioarctic Ab Antitela koja vezuju alfa-sinuklein protofibril
US20230365665A1 (en) 2020-09-17 2023-11-16 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
EP4367516A1 (en) 2021-07-09 2024-05-15 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
US20240352109A1 (en) 2021-08-30 2024-10-24 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
MX2024009492A (es) 2022-02-02 2024-08-09 Eisai R&D Man Co Ltd Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181).
JP2023132247A (ja) * 2022-03-10 2023-09-22 公立大学法人大阪 シヌクレイノパシー検出用バイオマーカー及びその利用
CN117430686B (zh) * 2022-07-22 2025-07-01 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用
CN116589567B (zh) * 2022-11-30 2024-03-19 西南大学 马铃薯x病毒单克隆抗体pvx-2及其应用
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2026068513A1 (en) 2024-09-24 2026-04-02 Bioarctic Ab Bispecific binding molecule

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754062B2 (en) 1998-07-03 2002-10-31 Innogenetics N.V. Differential diagnosis of neurodegeneration
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
MXPA06004853A (es) * 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US7553639B2 (en) 2006-01-31 2009-06-30 Elan Pharma International Limited Alpha-synuclein kinase
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CN101161245B (zh) * 2007-11-29 2011-11-09 首都医科大学宣武医院 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

Similar Documents

Publication Publication Date Title
JP2013525266A5 (https=)
HRP20180230T1 (hr) Protutijela koja se vežu na protofibrile i njihova upotreba u terapijskim i dijagnostičkim postupcima kod parkinsonove bolesti, demencije s lewyjevim tijelima i drugih alfa-sinukleinopatija
JP2016511254A5 (https=)
JP2021501744A5 (https=)
JP2013519364A5 (https=)
JP2016503065A5 (https=)
AR112816A2 (es) Compuestos que inhiben el enlace de la proteína smac al inhibidor de proteínas de apoptosis (iap)
EP3583212A4 (en) METHOD FOR PREPARING NUCLEIC ACID LIBRARIES AND COMPOSITIONS AND KITS FOR CARRYING OUT THEREOF
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
JP2011511624A5 (https=)
JP2015514110A5 (https=)
JP2010506596A5 (https=)
RU2015143886A (ru) Антитела к тау и способы применения
HRP20131066T1 (hr) Sp35 antitijela i njihova upotreba
CY1112374T1 (el) Επιλεκτικα του υποτυπου νικοτινικου υποδοχεα της ακετυλχολινης αμιδια διαζαδικυκλοαλκανιων
JP2016502515A5 (https=)
JP2015517300A5 (https=)
JP2011528561A5 (https=)
JP2013542194A5 (https=)
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
JP2011173884A5 (https=)
JP2011528901A5 (https=)
JP2017515792A5 (https=)
JP2014508748A5 (https=)
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.